Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


B-I's all oral, interferon-free combo regimen meets PhIIb goals in HCV genotype-1 patients

This article was originally published in Scrip

Executive Summary

Boehringer Ingelheim said that its interferon-free therapy – combining the company’s investigational direct-acting antiviral compounds - met the goals in treating HCV in genotype-1 patients after a pre-specified interim analysis of the ongoing, 362-patient Phase IIb SOUND-C2 trial. Most significantly, a subgroup of this hard-to-treat population, those with two prevalent types of HCV found across Europe and Asia (genotype-1a CC and -1b), had viral cure rates (SVR12) without interferon in up to 82% of patients after just 28 weeks of treatment.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts